Evolve Healthcare Partners

Founding partners Jordi Sabé and Ferdinand Mayer lead the firm. Sabé brings corporate development and advisory experience from Almirall and Advent International, while Mayer's background spans European healthcare investment banking at Nomura and Piper Jaffrey, plus direct investing at Goodgrower.

Evolve's sourcing advantage derives from its principals' and operating partners' executive networks across the European pharmaceutical and med-tech industries. Founding Partner Jordi Sabé was an Industry Advisor at Advent International and sits on the board of Cantabria Labs; Advisory Partner Eduardo Sanchiz is the former CEO of Almirall. These relationships create a channel into founder- and family-owned healthcare companies across the continent.

Evolve Healthcare Partners is a mid-market private equity firm — an asset manager — not a family office. It co-invests alongside institutional limited partners such as Schroder Adveq, as demonstrated in the April 2021 Cera Care transaction.

Evolve Healthcare Partners executes direct buyout and growth-equity investments in European healthcare companies. Its structure does not publicly describe a fund-of-funds program; the firm co-invests its own capital alongside institutional co-investors in specific platform deals.

Evolve targets mid-market buyouts in European healthcare, with a focus on companies requiring growth acceleration or strategic repositioning — both organically and through M&A. The Cera Care investment in 2021 reflects a later-stage, growth-focused capital injection into an established digital health platform rather than early-stage venture.